Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34102137

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2021 Jul 3
First author
Janjigian YY

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2021 Jul 3;398(10294):2-3. doi: 10.1016/S0140-6736(21)00988-0.
    note
    Source null
    related pmid
    34102138
    relationship
    Comment in
  2. citation
    Nat Cancer. 2021 Dec;2(12):1286. doi: 10.1038/s43018-021-00308-3.
    note
    Source null
    related pmid
    35121910
    relationship
    Comment in
  3. citation
    Natl Med J India. 2022 Mar-Apr;35(2):98-99. doi: 10.25259/NMJI_645_21.
    note
    Source null
    related pmid
    36461855
    relationship
    Comment in
  4. citation
    Lancet Gastroenterol Hepatol. 2024 Jun;9(6):495-497. doi: 10.1016/S2468-1253(24)00043-8.
    note
    Source null
    related pmid
    38492581
    relationship
    Comment in
  5. citation
    Lancet. 2024 Jul 27;404(10450):337-338. doi: 10.1016/S0140-6736(24)01045-6.
    note
    Source null
    related pmid
    39067898
    relationship
    Comment in

Authors and identifiers

  1. name
    Janjigian YY
    type
    Author
  2. name
    Shitara K
    type
    Author
  3. name
    Moehler M
    type
    Author
  4. name
    Garrido M
    type
    Author
  5. name
    Salman P
    type
    Author
  6. name
    Shen L
    type
    Author
  7. name
    Wyrwicz L
    type
    Author
  8. name
    Yamaguchi K
    type
    Author
  9. name
    Skoczylas T
    type
    Author
  10. name
    Campos Bragagnoli A
    type
    Author
  11. name
    Liu T
    type
    Author
  12. name
    Schenker M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Janjigian YY
    type
    Author
  2. name
    Shitara K
    type
    Author
  3. name
    Moehler M
    type
    Author
  4. name
    Garrido M
    type
    Author
  5. name
    Salman P
    type
    Author
  6. name
    Shen L
    type
    Author
  7. name
    Wyrwicz L
    type
    Author
  8. name
    Yamaguchi K
    type
    Author
  9. name
    Skoczylas T
    type
    Author
  10. name
    Campos Bragagnoli A
    type
    Author
  11. name
    Liu T
    type
    Author
  12. name
    Schenker M
    type
    Author
bibliography ids
  1. nci-bib-cb11689d51151dc3d3bde66a
book metadata
content sha256
8e8bc47f347969a5a77574c12f079abbc97f9cec3113d03424188e23e861dabf
document type
citation
dois
  1. 10.1016/S0140-6736(21)00797-2
electronic publication date
display
2021 Jun 5
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:34102137
immutable id
pubmed:34102137@8e8bc47f347969a5a77574c12f079abbc97f9cec3113d03424188e23e861dabf
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10294
name
Lancet (London, England)
nlm unique id
2985213R
pages
27-40
volume
398
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2021 Jul 3;398(10294):2-3. doi: 10.1016/S0140-6736(21)00988-0.
    note
    Source null
    related pmid
    34102138
    relationship
    Comment in
  2. citation
    Nat Cancer. 2021 Dec;2(12):1286. doi: 10.1038/s43018-021-00308-3.
    note
    Source null
    related pmid
    35121910
    relationship
    Comment in
  3. citation
    Natl Med J India. 2022 Mar-Apr;35(2):98-99. doi: 10.25259/NMJI_645_21.
    note
    Source null
    related pmid
    36461855
    relationship
    Comment in
  4. citation
    Lancet Gastroenterol Hepatol. 2024 Jun;9(6):495-497. doi: 10.1016/S2468-1253(24)00043-8.
    note
    Source null
    related pmid
    38492581
    relationship
    Comment in
  5. citation
    Lancet. 2024 Jul 27;404(10450):337-338. doi: 10.1016/S0140-6736(24)01045-6.
    note
    Source null
    related pmid
    39067898
    relationship
    Comment in
outcomes validated
false
pmid
34102137
provenance
batch id
79f1021053e858d13ff3
provider
NCBI PubMed ESummary
record sha256
45e008a07b8fb7c793849e7aa1c28ce7e686a2c5979f1eead4c7e162f5a885b2
response sha256
671d3d2962f73c698a1cb338d73222e2cc6cfdf61569f91b42612d5b59822e05
retrieved at
2026-09-09T23:47:59.098265+00:00
publication date
display
2021 Jul 3
precision
day
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34102137/
title
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.

Preserved source evidence · Not medical advice